(Prostate Cancer) Is PARP Inhibitor Rucaparib Effective?
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
On August 14, 2020, Wassim Abida published results in the Journal of Clinical Oncology from the TRITON2 Phase 2 clinical trial evaluating the efficacy and safety of the PARP inhibitor Rucaparib in patients with BRCA1/BRCA2 gene mutation-positive, metastatic castration-resistant prostate cancer.
The TRITON2 Phase 2 trial enrolled 115 previously treated patients with BRCA1/BRCA2 mutation-positive metastatic castration-resistant prostate cancer, who received Rucaparib monotherapy twice daily. The primary endpoints were objective response rate (ORR) and PSA response rate.
Approximately 12% of metastatic castration-resistant prostate cancer patients carry BRCA1 or BRCA2 gene mutations. These mutations increase the risk of prostate cancer development and metastasis. Because PARP inhibitors can suppress homologous recombination repair defects and DNA damage responses caused by BRCA1/BRCA2 mutations, they were expected to benefit this patient population.
Results:
- Primary endpoint ORR (IRC-assessed): 43.5%
- Primary endpoint ORR (investigator-assessed): 50.8%
- PSA response rate: 54.8%
Conclusion: Based on the TRITON2 trial results, Wassim Abida concluded that Rucaparib demonstrated meaningful anti-tumor activity in BRCA1/BRCA2 mutation-positive metastatic castration-resistant prostate cancer patients, with a safety profile consistent with previously known adverse event data from other clinical trials.
Disclaimer: Medical Supporter translates overseas clinical trial data and pharmaceutical information for informational purposes only. Translation materials are for reference only. Please consult your healthcare provider for medical decisions.
Source: Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration. J Clin Oncol. 2020 Aug 14; JCO2001035. doi: 10.1200/JCO.20.01035.
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4